Ligand-Activated Peroxisome Proliferator-Activated Receptor-γ Protects Against Ischemic Cerebral Infarction and Neuronal Apoptosis by 14-3-3∈ Upregulation

被引:103
|
作者
Wu, Jui-Sheng [2 ,3 ]
Cheung, Wai-Mui [2 ]
Tsai, Yau-Sheng [4 ]
Chen, Yi-Tong [2 ]
Fong, Wen-Hsuan [2 ]
Tsai, Hsin-Da [2 ]
Chen, Yu-Chang [2 ]
Liou, Jun-Yang [1 ]
Shyue, Song-Kun [2 ]
Chen, Jin-Jer [2 ]
Chen, Y. Eugene [5 ]
Maeda, Nobuyo [6 ]
Wu, Kenneth K. [1 ,7 ]
Lin, Teng-Nan [2 ]
机构
[1] Natl Hlth Res Inst, Zhunan Township 350, Miaoli County, Taiwan
[2] Acad Sinica, Taipei 115, Taiwan
[3] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan
[4] Natl Cheng Kung Univ, Coll Med, Grad Inst Clin Med, Tainan 70101, Taiwan
[5] Univ Michigan, Med Ctr, Ctr Cardiovasc, Ann Arbor, MI USA
[6] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA
[7] Univ Texas Houston, Hlth Sci Ctr, Houston, TX USA
基金
美国国家卫生研究院;
关键词
apoptosis; infarction; stroke; PPAR gamma; PPAR-GAMMA; GLUCOSE DEPRIVATION; 14-3-3; PROTEINS; BRAIN; 14-3-3-PROTEINS; EXPRESSION; TRANSIENT; SURVIVAL; J(2); BAD;
D O I
10.1161/CIRCULATIONAHA.108.812537
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Thiazolidinediones have been reported to protect against ischemia-reperfusion injury. Their protective actions are considered to be peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-dependent; however, it is unclear how PPAR-gamma activation confers resistance to ischemia-reperfusion injury. Methods and Results We evaluated the effects of rosiglitazone or PPAR-gamma overexpression on cerebral infarction in a rat model and investigated the antiapoptotic actions in the N2-A neuroblastoma cell model. Rosiglitazone or PPAR-gamma overexpression significantly reduced infarct volume. The protective effect was abrogated by PPAR-gamma small interfering RNA. In mice with knock-in of a PPAR-gamma dominant-negative mutant, infarct volume was enhanced. Proteomic analysis revealed that brain 14-3-3 is an element of was highly upregulated in rats treated with rosiglitazone. Upregulation of 14-3-3 is an element of was abrogated by PPAR-gamma small interfering RNA or antagonist. Promoter analysis and chromatin immunoprecipitation revealed that rosiglitazone induced PPAR-gamma binding to specific regulatory elements on the 14-3-3 is an element of promoter and thereby increased 14-3-3 is an element of transcription. 14-3-3 is an element of Small interfering RNA abrogated the antiapoptotic actions of rosiglitazone or PPAR-gamma overexpression, whereas 14-3-3 is an element of recombinant proteins rescued brain tissues and N2-A cells from ischemia-induced damage and apoptosis. Elevated 14-3-3 is an element of enhanced binding of phosphorylated Bad and protected mitochondrial membrane potential. Conclusions Ligand-activated PPAR-gamma confers resistance to neuronal apoptosis and cerebral infarction by driving 14-3-3 is an element of transcription. 14-3-3 is an element of Upregulation enhances sequestration of phosphorylated Bad and thereby suppresses apoptosis. (Circulation. 2009; 119: 1124-1134.)
引用
收藏
页码:1124 / 1134
页数:11
相关论文
共 50 条
  • [31] Sequential backbone assignment of peroxisome proliferator-activated receptor-γ ligand binding domain
    Riepl, H
    Hartl, R
    Bauer, M
    Nar, H
    Kauschke, SG
    Kalbitzer, HR
    Maurer, T
    JOURNAL OF BIOMOLECULAR NMR, 2005, 32 (03) : 259 - 259
  • [32] Effects of Peroxisome Proliferator-Activated Receptor-γ Activation on Apoptosis in Rats with Acute Pancreatitis
    Xu, Ping
    Lou, Xiao-Li
    Chen, Cheng
    Yang, Zhi-Wen
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (12) : 3516 - 3523
  • [33] Effects of Peroxisome Proliferator-Activated Receptor-γ Activation on Apoptosis in Rats with Acute Pancreatitis
    Ping Xu
    Xiao-Li Lou
    Cheng Chen
    Zhi-Wen Yang
    Digestive Diseases and Sciences, 2013, 58 : 3516 - 3523
  • [34] Aleglitazar, a dual peroxisome proliferator-activated receptor- and - agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia
    Chen, Yan
    Chen, Hongmei
    Birnbaum, Yochai
    Nanhwan, Manjyot K.
    Bajaj, Mandeep
    Ye, Yumei
    Qian, Jinqiao
    DIABETES & VASCULAR DISEASE RESEARCH, 2017, 14 (02): : 152 - 162
  • [35] 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-α
    Fang, X
    Hu, SM
    Xu, BK
    Snyder, GD
    Harmon, S
    Yao, JR
    Liu, Y
    Sangras, B
    Falck, JR
    Weintraub, NL
    Spector, AA
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (01): : H55 - H63
  • [36] Activation of peroxisome proliferator-activated receptor-α protects the heart from ischemia/reperfusion injury
    Yue, TL
    Bao, W
    Jucker, BM
    Gu, JL
    Romanic, AM
    Brown, PJ
    Cui, JQ
    Thudium, DT
    Boyce, R
    Burns-Kurtis, CL
    Mirabile, RC
    Aravindhan, K
    Ohlstein, EH
    CIRCULATION, 2003, 108 (19) : 2393 - 2399
  • [37] Role of the peroxisome proliferator-activated receptor-γ in neuronal differentiation induced by AT1-receptor antagonists
    Hélder Pinheiro
    Joana Catarata
    Conceição Calhau
    Daniel Moura
    Pharmacological Reports, 2013, 65 (Suppl 1) : 73 - 73
  • [38] Ligand-Activated Peroxisome Proliferator-Activated Receptor δ Attenuates Vascular Oxidative Stress by Inhibiting Thrombospondin-1 Expression
    Ahn, Min Young
    Ham, Sun Ah
    Yoo, Taesik
    Lee, Won Jin
    Hwang, Jung Seok
    Paek, Kyung Shin
    Lim, Dae-Seog
    Han, Sung Gu
    Lee, Chi-Ho
    Seo, Han Geuk
    JOURNAL OF VASCULAR RESEARCH, 2018, 55 (02) : 75 - 86
  • [39] Rosiglitazone, a peroxisome proliferator-activated receptor-γ ligand, reduces infarction volume and neurological deficits in an embolic model of stroke
    Allahtavakoli, Mohammad
    Shabanzadeh, Alireza P.
    Sadr, Seyed Shahabeddin
    Parviz, Mohsen
    Djahanguiri, Bijan
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (11) : 1052 - 1058
  • [40] Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-γ ligand therapy
    Bishop-Bailey, D
    Hla, T
    Warner, TD
    CIRCULATION RESEARCH, 2002, 91 (03) : 210 - 217